MCID: VGT001
MIFTS: 48

Vogt-Koyanagi-Harada Disease malady

Rare diseases, Neuronal diseases, Eye diseases, Immune diseases categories

Aliases & Classifications for Vogt-Koyanagi-Harada Disease

About this section
Sources:
10Disease Ontology, 45NIH Rare Diseases, 47Novoseek, 12DISEASES, 51Orphanet, 65UMLS, 36MeSH, 59SNOMED-CT, 42NCIt, 29ICD9CM, 28ICD10 via Orphanet
See all sources

Aliases & Descriptions for Vogt-Koyanagi-Harada Disease:

Name: Vogt-Koyanagi-Harada Disease 10 45 47 12 51
Uveomeningoencephalitic Syndrome 10 65 36
Uveomenigitic Syndrome 45 51
Vogt-Koyanagi-Harada Syndrome 45
 
Vogt-Koyanagi Syndrome 10
Harada's Disease 10
Vkh Syndrome 45
Vkh Disease 45


Classifications:



Characteristics (Orphanet epidemiological data):

51
vogt-koyanagi-harada disease:
Inheritance: Multigenic/multifactorial; Age of onset: All ages; Age of death: normal life expectancy


External Ids:

Disease Ontology10 DOID:12297
NCIt42 C85218
ICD9CM29 363.22, 364.24
MeSH36 D014607
Orphanet51 3437
ICD10 via Orphanet28 H20.8, H30.8

Summaries for Vogt-Koyanagi-Harada Disease

About this section
NIH Rare Diseases:45 Vogt-koyanagi-harada disease (vkh disease) is a condition that involves chronic inflammation of melanocytes, which are specialized cells that produce a pigment called melanin. melanin is the substance that gives skin, hair, and eyes their color. melanin is also found in the retina, where it plays a role in normal vision. people with vkh disease usually develop vision and hearing disturbances first, followed by signs of skin problems. the most common symptoms include headaches, panuveitis, vitiligo, hair loss (alopecia), and inner ear disturbances. neurological symptoms may also occur. the exact cause of vkh disease is not well understood, but research suggests it is an autoimmune disease. it is more common in people with darker skin pigmentation including asian, middle eastern, hispanic, and native american populations. last updated: 1/8/2015

MalaCards based summary: Vogt-Koyanagi-Harada Disease, also known as uveomeningoencephalitic syndrome, is related to uveitis and choroid disease, and has symptoms including sensorineural hearing impairment, abnormality of the eyelashes and visual impairment. An important gene associated with Vogt-Koyanagi-Harada Disease is PTPN22 (Protein Tyrosine Phosphatase, Non-Receptor Type 22 (Lymphoid)), and among its related pathways are Antigen Presentation- Folding, assembly and peptide loading of class I MHC and IL12 signaling mediated by STAT4. Affiliated tissues include eye, skin and retina, and related mouse phenotypes are immune system and mortality/aging.

Disease Ontology:10 A hypersensitivity reaction type ii disease that is caused by t helper cell mediated autoimmune attack of melanocytes resulting in inflammation of the inside of the eye, whitening of hair, skin pigment loss, and meningitis.

Related Diseases for Vogt-Koyanagi-Harada Disease

About this section

Graphical network of the top 20 diseases related to Vogt-Koyanagi-Harada Disease:



Diseases related to vogt-koyanagi-harada disease

Symptoms for Vogt-Koyanagi-Harada Disease

About this section

Symptoms:

 51 (show all 13)
  • mild visual loss/impaired visual acuity
  • absent/decreased/thin eyebrows
  • absent/decreased lashes
  • sensorineural deafness/hearing loss
  • irregular/patchy skin hypopigmentation
  • hypotrichosis/atrichia/atrichiasis/scalp hairlessness
  • premature greying of hair
  • intellectual deficit/mental/psychomotor retardation/learning disability
  • glaucoma
  • cataract/lens opacification
  • retinal detachment
  • visual loss/blindness/amblyopia
  • short stature/dwarfism/nanism

HPO human phenotypes related to Vogt-Koyanagi-Harada Disease:

(show all 13)
id Description Frequency HPO Source Accession
1 sensorineural hearing impairment hallmark (90%) HP:0000407
2 abnormality of the eyelashes hallmark (90%) HP:0000499
3 visual impairment hallmark (90%) HP:0000505
4 hypopigmented skin patches hallmark (90%) HP:0001053
5 premature graying of hair hallmark (90%) HP:0002216
6 abnormal hair quantity hallmark (90%) HP:0011362
7 cognitive impairment hallmark (90%) HP:0100543
8 aplasia/hypoplasia of the eyebrow hallmark (90%) HP:0100840
9 glaucoma typical (50%) HP:0000501
10 visual impairment typical (50%) HP:0000505
11 cataract typical (50%) HP:0000518
12 retinal detachment typical (50%) HP:0000541
13 short stature typical (50%) HP:0004322

Drugs & Therapeutics for Vogt-Koyanagi-Harada Disease

About this section

Drugs for Vogt-Koyanagi-Harada Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 9)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Bevacizumabapproved, investigationalPhase 31820216974-75-3
Synonyms:
216974-75-3
Avastin
Avastin (TN)
Bevacizumab
Bevacizumab (genetical recombination)
 
Bevacizumab (genetical recombination) (JAN)
D06409
R-435
anti-VEGF monoclonal antibody
antiVEGF
bevacizumab
2
Mycophenolate mofetilapproved, investigational864128794-94-55281078
Synonyms:
115007-34-6
128794-94-5
140401-05-4
2-Morpholinoethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-Morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-Morpholinoethyl (e)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-morpholin-4-ylethyl (4E)-6-[4-hydroxy-7-methyl-6-(methyloxy)-3-oxo-1,3-dihydro-2-benzofuran-5-yl]-4-methylhex-4-enoate
2-morpholin-4-ylethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoate
4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl -3-oxo-5-isobenzofuranyl)-4-methyl-, 2-(4-morpholinyl)ethyl ester, (4E)
AC-1562
AC1NQXZW
AC1Q6O6X
AR-1J6939
BB_NC-2566
C07908
C23H31NO7
CHEMBL1456
CID5281078
CellCept
CellCept, RS 61443, TM-MMF, Mycophenolate mofetil
Cellcept
Cellcept (TN)
D00752
DB00688
HMS2090A03
 
HSDB 7436
I01-0898
I06-1947
LS-172272
LS-75572
ME-MPA
MMF
MMF CellCept(TM)
MolPort-000-883-800
Munoloc
Mycophenolate Mofetil
Mycophenolate mofetil (JAN/USAN)
Mycophenolic acid morpholinoethyl ester
Mycophenylate mofetil
NCGC00159459-02
NCGC00159459-03
NSC724229
R-99
RS 61443
RS-61443
RS-61443-190
S1501_Selleck
TL8000648
TM-MMF
UNII-9242ECW6R0
ZINC21297660
mycophenolate mofetil
3
Azathioprineapproved145446-86-62265
Synonyms:
446-86-6
55774-33-9 (hydrochloride salt)
6-((1-Methyl-4-nitro-1H-imidazol-5-yl)thio)-1H-purine
6-((1-Methyl-4-nitroimidazol-5-yl)thio)purine
6-(1'-Methyl-4'-nitro-5'-imidazolyl)-mercaptopurine
6-(1'-Methyl-4'-nitro-5'-imidazolyl)mercaptopurine
6-(1-Methyl-4-nitroimidazol-5-yl)thiopurine
6-(1-Methyl-4-nitroimidazol-5-ylthio)purin
6-(1-Methyl-4-nitroimidazol-5-ylthio)purin [Czech]
6-(1-Methyl-p-nitro-5-imidazolyl)-thiopurine
6-(1-Methyl-p-nitro-5-imidazolyl)thiopurine
6-(3-Methyl-5-nitro-3H-imidazol-4-ylsulfanyl)-7H-purine
6-(3-methyl-5-nitroimidazol-4-yl)sulfanyl-7H-purine
6-(Methyl-p-nitro-5-imidazolyl)-thiopurine
6-(Methyl-p-nitro-5-imidazolyl)thiopurine
6-({4-nitro-1-methyl-1H-imidazol-5-yl}sulfanyl)-7H-purine
6-1'-Methyl,4'-nitro,5'-imidazolyl mercaptopurine
6-[(1-Methyl-4-nitroimidazol-5-yl)- thio] purine
6-[(1-Methyl-4-nitroimidazol-5-yl)thio]purine
6-[(1-methyl-4-nitro-1H-imidazol-5-yl)sulfanyl]-7H-purine
6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-1H-Purine
6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-7H-purine
6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-9H-purine
A 4638
A2593_SIAL
A4638_SIAL
A4638_SIGMA
AB00443544
AB00443544-03
AC-4230
AC1L1DAL
AC1Q3Z1F
AI-981/34845012
AI3-50290
Azamun
Azamun [Czech]
Azanin
Azasan
Azasan (TN)
Azasan, Imuran, Azamun, BW-57-322, NSC-39084, Azathioprine
Azathioprin
Azathioprine
Azathioprine (JP15/USP/INN)
Azathioprine Sodium
Azathioprine [USAN:INN:BAN:JAN]
Azathioprine sodium
Azathioprinum
Azathioprinum [INN-Latin]
Azathiopurine
Azatioprin
Azatioprina
Azatioprina [INN-Spanish]
Azothioprine
B. W. 57-322
BPBio1_000054
BRD-K32821942-001-05-6
BRD-K60324116-001-01-5
BSPBio_000048
BSPBio_001876
BW 57-322
BW 57322
BW-57-322
C06837
C9H7N7O2S
CAS-446-86-6
CBDivE_013132
CCRIS 62
CHEBI:2948
CHEMBL1542
CID2265
CPD000427366
Ccucol
ChemDiv1_002659
Cytostatics
D00238
DB00993
DivK1c_000586
EINECS 207-175-4
EU-0100027
FT-0083532
HMS1568C10
 
HMS1920E17
HMS2091K19
HMS501N08
HMS594I19
HSDB 7084
IDI1_000586
Immuran
Imuran
Imuran (TN)
Imuran (tn)
Imurek
Imurel
KBio1_000586
KBio2_000464
KBio2_002427
KBio2_003032
KBio2_004995
KBio2_005600
KBio2_007563
KBio3_001376
KBio3_002906
KBioGR_000646
KBioGR_002427
KBioSS_000464
KBioSS_002433
LS-123
Lopac-A-4638
Lopac0_000027
MLS001049307
Methylnitroimidazolylmercaptopurine
MolPort-000-745-914
MolPort-000-764-262
MolPort-003-665-485
Muran
NCGC00015060-01
NCGC00015060-02
NCGC00015060-04
NCGC00015060-12
NCGC00090836-01
NCGC00090836-02
NCGC00090836-03
NCGC00090836-04
NCGC00090836-05
NCGC00090836-06
NCGC00094593-01
NCGC00094593-02
NCGC00094593-03
NCI-C03474
NINDS_000586
NSC 39084
NSC-39084
NSC39084
Oprea1_375441
Oprea1_533384
Oprea1_633462
Prestwick0_000094
Prestwick1_000094
Prestwick2_000094
Prestwick3_000094
Prestwick_41
S1721_Selleck
SAM002589938
SDCCGMLS-0065415.P001
SMR000427366
SPBio_000255
SPBio_001987
SPECTRUM1500133
STK831906
STOCK1S-20293
STOCK1S-27186
Spectrum2_000068
Spectrum3_000308
Spectrum4_000243
Spectrum5_000848
Spectrum_000064
Thiopurine 6-(1-methyl-4-nitroimidazol-5-yl)
UNII-MRK240IY2L
WLN: T56 BM DN FN HNJ IS- ET5N CNJ A1 DNW
ZINC04258316
[Methyl(nitroimidazolyl)mercaptopurine]
azathioprine
azatiopr in
cMAP_000046
4
Mycophenolic acidapproved86424280-93-1446541
Synonyms:
(e)-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acid
Acide mycophenolique
Acido micofenolico
Acidum mycophenolicum
Melbex
 
Micofenolico acido
Mycophenoic acid
Mycophenolate
Mycophenolic Acid
Mycophenolsaeure
Myfortic
5Povidone-Iodine117
6Povidone114
7
Iodine4597553-56-2807
Synonyms:
I2
Iode
Iodine-molecule
 
Iodio
Iodum
Jod
Jood
Tincture iodine
8cadexomer iodine425
9Cyclosporins849

Interventional clinical trials:

idNameStatusNCT IDPhase
1Intravitreal Bevacizumab for Inflammatory Neovascular MembranesCompletedNCT00407121Phase 3
2Safety and Efficacy of AIN457 in Noninfectious UveitisCompletedNCT00685399Phase 2
3Intravitreal Bevacizumab for the Treatment of CNV in VKH Disease - A Prospective StudyActive, not recruitingNCT02015351

Search NIH Clinical Center for Vogt-Koyanagi-Harada Disease


Cochrane evidence based reviews: Uveomeningoencephalitic Syndrome

Genetic Tests for Vogt-Koyanagi-Harada Disease

About this section

Anatomical Context for Vogt-Koyanagi-Harada Disease

About this section

MalaCards organs/tissues related to Vogt-Koyanagi-Harada Disease:

33
Eye, Skin, Retina, T cells, Ovary, Liver, Spinal cord

Animal Models for Vogt-Koyanagi-Harada Disease or affiliated genes

About this section

MGI Mouse Phenotypes related to Vogt-Koyanagi-Harada Disease:

38
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053877.5CD8A, HLA-B, HLA-DQB1, IL17A, IL2RA, PTPN22
2MP:00107686.4CD8A, HLA-B, HLA-DQB1, IL17A, IL2RA, PTPN22

Publications for Vogt-Koyanagi-Harada Disease

About this section

Articles related to Vogt-Koyanagi-Harada Disease:

(show top 50)    (show all 310)
idTitleAuthorsYear
1
Analysis of choroidal folds in acute Vogt-Koyanagi-Harada disease using high-penetration optical coherence tomography. (25663475)
2015
2
DETECTION OF CHOROIDAL FOLDS IN PATIENTS WITH VOGT-KOYANAGI-HARADA DISEASE BY RETROMODE SCANNING LASER OPHTHALMOSCOPY. (26444520)
2015
3
Pseudotumoral and Multiple Retinal Pigment Epithelium Proliferation in Vogt-Koyanagi-Harada Disease. (26509089)
2015
4
Clinical Outcomes of Patients with Vogt-Koyanagi-Harada Disease Over 12 Years at a Tertiary Center. (26399962)
2015
5
Association of HLA-DR4/HLA-DRB1*04 with Vogt-Koyanagi-Harada disease: A Systematic Review and Meta-analysis. (25382027)
2014
6
Decreased Interleukin-37 Expression in Vogt-Koyanagi-Harada Disease and Upregulation Following Immunosuppressive Treatment. (25343528)
2014
7
Influence of molecular genetics in Vogt-Koyanagi-Harada disease. (25097674)
2014
8
Cluster-like headache as presenting feature of Vogt-Koyanagi-Harada disease. (25591688)
2014
9
Choroidal atrophy and loss of choriocapillaris in convalescent stage of Vogt-Koyanagi-Harada disease: in vivo documentation. (24655594)
2014
10
Vogt-koyanagi-harada disease in an adolescent boy. (23869531)
2014
11
Vogt-Koyanagi-Harada disease in First Nations and MActis of Northern Alberta. (23769774)
2013
12
Retinal pigment epithelium folds as a diagnostic finding of Vogt-Koyanagi-Harada disease. (23149670)
2013
13
Indocyanine green angiography-guided management of Vogt-Koyanagi-Harada disease: differentiation between choroidal scars and active lesions. (23277207)
2013
14
Vogt-Koyanagi-Harada disease masquerading as a lymphoproliferative process of the uvea. (23913248)
2013
15
Vogt-Koyanagi-Harada disease: a forgotten entity in the Canadian uveitis landscape? (23769771)
2013
16
Vogt-Koyanagi-Harada disease in Thailand. (23163754)
2012
17
Probable Vogt-Koyanagi-Harada disease with initial unilateral ocular manifestation in a hepatitis C carrier. (22588777)
2012
18
Decreased IL-27 expression in association with an increased Th17 response in Vogt-Koyanagi-Harada disease. (22669715)
2012
19
Vogt-Koyanagi-Harada disease presenting as acute angle closure glaucoma at onset. (22452682)
2011
20
Intravitreal triamcinolone acetonide for rebound phenomenon after high-dose intravenous steroid treatment in Vogt-Koyanagi-Harada disease. (22125406)
2011
21
Suboptimal therapy controls clinically apparent disease but not subclinical progression of Vogt-Koyanagi-Harada disease. (19151926)
2010
22
Blue light and near-infrared fundus autofluorescence in acute Vogt-Koyanagi-Harada disease. (19965835)
2010
23
Morphologic changes in the anterior segment in patients with initial-onset or recurrent Vogt-Koyanagi-Harada disease. (20662662)
2010
24
The prognostic value of angiography in Vogt-Koyanagi-Harada disease. (20933219)
2010
25
Indocyanine green angiography findings in initial acute pretreatment Vogt-Koyanagi-Harada disease in Japanese patients. (21052896)
2010
26
Frequency of distinguishing clinical features in Vogt-Koyanagi-Harada disease. (20036008)
2010
27
Vogt-Koyanagi-Harada disease and vitiligo: where does the illness begin? (18174263)
2008
28
Elevated choroidal blood flow velocity during systemic corticosteroid therapy in Vogt-Koyanagi-Harada disease. (19016661)
2008
29
Thunderclap headache as initial manifestation of Vogt-Koyanagi-Harada disease. (17868357)
2008
30
Characteristics of Vogt-Koyanagi-Harada disease in a French cohort: ethnicity, systemic manifestations, and HLA genotype data. (18379934)
2008
31
Vitreous surgery for macular hole in patients with Vogt-Koyanagi-Harada disease. (19278482)
2008
32
Concomitant choroidal inflammation during anterior segment recurrence in Vogt-Koyanagi-Harada disease. (18191100)
2008
33
Vogt-Koyanagi-Harada disease: inquiry into the genesis of a disease name in the historical context of Switzerland and Japan. (17468832)
2007
34
Cross-reaction between tyrosinase peptides and cytomegalovirus antigen by T cells from patients with Vogt-Koyanagi-Harada disease. (17253112)
2007
35
The spectrum of Vogt-Koyanagi-Harada disease in Turkey: VKH in Turkey. (16957877)
2007
36
IL-23 promotes CD4+ T cells to produce IL-17 in Vogt-Koyanagi-Harada disease. (17335887)
2007
37
Vogt-koyanagi-harada disease with onset in elderly patients aged 68 to 89 years. (17295144)
2007
38
Pathology of Vogt-Koyanagi-Harada disease. (17435969)
2007
39
Vogt-Koyanagi-Harada disease. (16770158)
2006
40
Vogt-Koyanagi-Harada disease in patients with chronic hepatitis C. (16310490)
2005
41
Early manifestation of vogt-koyanagi-harada disease as unilateral posterior scleritis. (12457922)
2002
42
Pathogenesis of Vogt-Koyanagi-Harada disease. (12189608)
2002
43
Sunset glow fundus in Vogt-Koyanagi-Harada disease with or without chronic ocular inflammation. (12397437)
2002
44
Tyrosinase family proteins are antigens specific to Vogt-Koyanagi-Harada disease. (11120868)
2000
45
HLA-DRB1*0405 is the predominant allele in Brazilian patients with Vogt-Koyanagi-Harada disease. (9548078)
1998
46
Tyrosinase epitope recognized by an HLA-DR-restricted T-cell line from a Vogt-Koyanagi-Harada disease patient. (9510558)
1998
47
Choroidal neovascularization in long-standing case of Vogt-Koyanagi-Harada disease. (6190031)
1983
48
Vitiligo with an inflammatory erythema in Vogt-Koyanagi-Harada disease: demonstration of filamentous masses and amyloid deposits. (7119218)
1982
49
Two cases of Vogt-Koyanagi-Harada disease. (13691273)
1960
50
Vogt-Koyanagi-Harada disease; treatment with prednisone. (13410236)
1957

Variations for Vogt-Koyanagi-Harada Disease

About this section

Expression for genes affiliated with Vogt-Koyanagi-Harada Disease

About this section
Search GEO for disease gene expression data for Vogt-Koyanagi-Harada Disease.

Pathways for genes affiliated with Vogt-Koyanagi-Harada Disease

About this section

Pathways related to Vogt-Koyanagi-Harada Disease according to GeneCards Suite gene sharing:

(show all 21)
idSuper pathways (with members indented)ScoreTop Affiliating Genes
19.8HLA-A, HLA-B
29.7HLA-DRB1, IL2RA
3
Show member pathways
9.3CD8A, HLA-A, HLA-DRB1
49.2CD8A, HLA-A, HLA-B
59.2CD8A, HLA-DRB1, IL2RA
6
Show member pathways
9.2CD8A, HLA-A, IL2RA
7
Show member pathways
9.1HLA-DQB1, HLA-DRB1, IL2RA
89.1HLA-DQB1, HLA-DRB1, IL17A
99.0HLA-DQB1, HLA-DRB1, IFNA2
10
Show member pathways
8.9CD8A, HLA-A, HLA-DRB1, IL2RA
118.8HLA-A, HLA-B, HLA-DQB1, HLA-DRB1
128.8HLA-A, HLA-B, HLA-DQB1, HLA-DRB1
138.8CD8A, IL17A, IL2RA, PTPN22
14
Show member pathways
8.8HLA-A, HLA-B, IFNA2, IL17A
158.7CD8A, HLA-DQB1, HLA-DRB1, PTPN22
168.4HLA-A, HLA-B, HLA-DQB1, HLA-DRB1, IL2RA
178.3CD8A, HLA-A, HLA-B, HLA-DQB1, HLA-DRB1
18
Show member pathways
8.3HLA-A, HLA-B, HLA-DQB1, HLA-DRB1, IFNA2
19
Show member pathways
7.9HLA-A, HLA-B, HLA-DQB1, HLA-DRB1, IFNA2, IL2RA
20
Show member pathways
7.4CD8A, HLA-A, HLA-B, HLA-DQB1, HLA-DRB1, IFNA2
21
Show member pathways
6.9CD8A, HLA-A, HLA-B, HLA-DQB1, HLA-DRB1, IFNA2

GO Terms for genes affiliated with Vogt-Koyanagi-Harada Disease

About this section

Cellular components related to Vogt-Koyanagi-Harada Disease according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1MHC class I protein complexGO:004261210.4HLA-A, HLA-B
2MHC class II protein complexGO:004261310.0HLA-DQB1, HLA-DRB1
3melanosome membraneGO:00331629.9TYR, TYRP1
4transport vesicle membraneGO:00306589.5HLA-DQB1, HLA-DRB1
5integral component of lumenal side of endoplasmic reticulum membraneGO:00715569.3HLA-A, HLA-B, HLA-DQB1, HLA-DRB1
6ER to Golgi transport vesicle membraneGO:00125079.3HLA-A, HLA-B, HLA-DQB1, HLA-DRB1
7clathrin-coated endocytic vesicle membraneGO:00306699.1HLA-DQB1, HLA-DRB1, TYRP1
8external side of plasma membraneGO:00098979.1CD8A, HLA-DRB1, IL17A, IL2RA
9Golgi membraneGO:00001398.5HLA-A, HLA-B, HLA-DQB1, HLA-DRB1
10cell surfaceGO:00099868.5CD8A, HLA-A, HLA-B, HLA-DRB1, IL2RA

Biological processes related to Vogt-Koyanagi-Harada Disease according to GeneCards Suite gene sharing:

(show all 21)
idNameGO IDScoreTop Affiliating Genes
1positive regulation of CD8-positive, alpha-beta T cell proliferationGO:200056610.5HLA-A, PTPN22
2antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independentGO:000248010.4HLA-A, HLA-B
3antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentGO:000248610.4HLA-A, HLA-B
4inflammatory response to antigenic stimulusGO:000243710.4HLA-DRB1, IL2RA
5positive regulation of T cell mediated cytotoxicityGO:000191610.4HLA-A, HLA-B
6protection from natural killer cell mediated cytotoxicityGO:004227010.3HLA-A, HLA-B
7negative regulation of T cell proliferationGO:004213010.2HLA-DRB1, IL2RA
8antigen processing and presentation of peptide or polysaccharide antigen via MHC class IIGO:000250410.2HLA-DQB1, HLA-DRB1
9immunoglobulin production involved in immunoglobulin mediated immune responseGO:000238110.2HLA-DQB1, HLA-DRB1
10humoral immune response mediated by circulating immunoglobulinGO:000245510.1HLA-DQB1, HLA-DRB1
11detection of bacteriumGO:001604510.0HLA-A, HLA-B, HLA-DRB1
12type I interferon signaling pathwayGO:00603379.8HLA-A, HLA-B, IFNA2
13pigmentationGO:00434739.8TYR, TYRP1
14melanin biosynthetic processGO:00424389.7TYR, TYRP1
15T cell receptor signaling pathwayGO:00508529.7HLA-DQB1, HLA-DRB1, PTPN22
16interferon-gamma-mediated signaling pathwayGO:00603339.4HLA-A, HLA-B, HLA-DQB1, HLA-DRB1
17regulation of immune responseGO:00507769.2CD8A, HLA-A, HLA-B
18antigen processing and presentationGO:00198828.7CD8A, HLA-A, HLA-B, HLA-DQB1, HLA-DRB1
19cell surface receptor signaling pathwayGO:00071668.7CD8A, IFNA2, IL17A, IL2RA
20cytokine-mediated signaling pathwayGO:00192218.2HLA-A, HLA-B, HLA-DQB1, HLA-DRB1, IFNA2
21immune responseGO:00069557.5CD8A, HLA-A, HLA-B, HLA-DQB1, HLA-DRB1, IL17A

Molecular functions related to Vogt-Koyanagi-Harada Disease according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1TAP bindingGO:004697710.0HLA-A, HLA-B
2MHC class II receptor activityGO:00323959.8HLA-DQB1, HLA-DRB1
3cytokine receptor bindingGO:00051269.6IFNA2, IL17A
4peptide antigen bindingGO:00426058.8HLA-A, HLA-B, HLA-DQB1, HLA-DRB1

Sources for Vogt-Koyanagi-Harada Disease

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet